中国普通外科杂志2025，Vol.34Issue(10)：2062-2067,6.DOI:10.7659/j.issn.1005-6947.250556
《IFSO关于临床肥胖患者在药物治疗诱导减重后的代谢减重手术声明》解读与思考
Interpretation and reflections on the IFSO statement on metabolic bariatric surgery after pharmacotherapy-induced weight loss in clinical obesity
何梦铖 1曹冲 1花荣 1邵怡凯 1姚琪远1
作者信息
- 1. 复旦大学附属华山医院 普通外科/肥胖疝外科中心,上海 200040
- 折叠
摘要
Abstract
Obesity is a major global public health challenge and a leading cause of multiple metabolic disorders,including hypertension and diabetes.In China,more than half of the adult population is overweight or obese.While anti-obesity pharmacotherapies(such as GLP-1 receptor agonists)and bariatric surgery have both advanced rapidly,strategies for integrating these two modalities remain unclear.In particular,controversies persist regarding surgical eligibility after drug discontinuation,and standardized clinical guidelines are lacking.In July 2025,the International Federation for the Surgery of Obesity and Metabolic Disorders released the world's first statement focusing on"metabolic bariatric surgery after pharmacotherapy-induced weight loss",which emphasizes the chronic disease model of obesity management and clarifies the synergistic relationship between pharmacotherapy and surgery.This article interprets the statement from the perspectives of treatment strategies,surgical eligibility,and drug-surgery coordination,aiming to provide evidence-based reference for clinicians and to promote standardized,integrated obesity management.关键词
减肥手术/胰高血糖素样肽-1受体激动剂/解读Key words
Bariatric Surgery/Glucagon-Like Peptide-1 Receptor Agonists/Interpretation分类
医药卫生引用本文复制引用
何梦铖,曹冲,花荣,邵怡凯,姚琪远..《IFSO关于临床肥胖患者在药物治疗诱导减重后的代谢减重手术声明》解读与思考[J].中国普通外科杂志,2025,34(10):2062-2067,6.
